Literature DB >> 19005476

Inter-regional comparisons of the prevalence of cardiometabolic risk factors in patients with hypertension in Europe: the GOOD survey.

C Farsang1, L Naditch-Brule, S Perlini, W Zidek, S E Kjeldsen.   

Abstract

The GOOD survey investigated the global cardiometabolic risk profile in adult patients with hypertension across 289 sites in four European regions (Northwest, Mediterranean, Atlantic European Mainland and Central Europe). Demographic, lifestyle, clinical and laboratory data were collected from eligible patients (n=3370) during a single clinic visit. In Central Europe, represented by Hungary, 44% of the participants had type II diabetes compared with 33% in the Atlantic European Mainland, and 26% in the Northwest and the Mediterranean regions. The prevalence of metabolic syndrome was also significantly higher in Central Europe (68%) and the Atlantic European Mainland (60%) than in the Northwest and the Mediterranean regions (50 and 52%, respectively). Fasting blood glucose, total cholesterol and triglyceride levels were all highest in Central Europe compared with the other three regions (P<0.001). In the Atlantic European Mainland, more patients had uncontrolled blood pressure (80%) compared with the other three regions (70-71%). Declared alcohol consumption was highest in the Atlantic European Mainland and exercise lowest in Central Europe. The prevalence of congestive heart failure, left ventricular hypertrophy, coronary artery disease and stable/unstable angina was higher in Central Europe compared with the other regions, whereas a family history of premature stroke or myocardial infarction, stroke, coronary revascularization and transient ischaemic attacks was all highest in the Atlantic European Mainland. These data indicate that many hypertensive patients across Europe have multiple cardiometabolic risk factors with the prevalence higher in Central Europe and the Atlantic European Mainland compared with Northwest and Mediterranean regions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19005476     DOI: 10.1038/jhh.2008.136

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  7 in total

1.  Metabolic syndrome: comparison of occurrence using three definitions in hypertensive patients.

Authors:  Adeseye A Akintunde; Olugbenga E Ayodele; Patience O Akinwusi; George O Opadijo
Journal:  Clin Med Res       Date:  2010-08-03

2.  Metabolic syndrome and masticatory hypofunction: a cross-sectional study.

Authors:  Mario Pérez-Sayáns; José R González-Juanatey; Alejandro I Lorenzo-Pouso; Cintia M Chamorro-Petronacci; Andrés Blanco-Carrión; Xabier Marichalar-Mendía; José M Somoza-Martín; Juan A Suárez-Quintanilla
Journal:  Odontology       Date:  2021-01-11       Impact factor: 2.634

3.  Prevalence, Awareness, Treatment, and Control of Hypertension in Romania: Results of the SEPHAR Study.

Authors:  M Dorobantu; R O Darabont; E Badila; S Ghiorghe
Journal:  Int J Hypertens       Date:  2010-02-01       Impact factor: 2.420

4.  Hypertension control and cardiometabolic risk: a regional perspective.

Authors:  Martin Thoenes; Peter Bramlage; Sam Zhong; Shuhua Shang; Massimo Volpe; David Spirk
Journal:  Cardiol Res Pract       Date:  2012-01-02       Impact factor: 1.866

5.  Blood pressure control and components of the metabolic syndrome: the GOOD survey.

Authors:  Walter Zidek; Lisa Naditch-Brûlé; Stefano Perlini; Csaba Farsang; Sverre E Kjeldsen
Journal:  Cardiovasc Diabetol       Date:  2009-09-15       Impact factor: 9.951

6.  Does the Prevalence of Dyslipidemias Differ between Newfoundland and the Rest of Canada? Findings from the Electronic Medical Records of the Canadian Primary Care Sentinel Surveillance Network.

Authors:  Shabnam Asghari; Erfan Aref-Eshghi; Oliver Hurley; Marshall Godwin; Pauline Duke; Tyler Williamson; Masoud Mahdavian
Journal:  Front Cardiovasc Med       Date:  2015-02-02

7.  Prevalence of cardiometabolic risk factors and selected cardiovascular diseases in hypertensive and normotensive participants in the adult Polish population: The WOBASZ II study.

Authors:  Arkadiusz Niklas; Justyna Marcinkowska; Magdalena Kozela; Andrzej Pająk; Tomasz Zdrojewski; Wojciech Drygas; Aleksandra Piwońska; Wojciech Bielecki; Krystyna Kozakiewicz; Andrzej Tykarski
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.